Skip to main content

Arrowhead Pharmaceuticals, Inc.

ARWR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000879407

In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.

13F holders, Q3 2024

Institutional positions in Arrowhead Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
272
+2 vs. Q2 2024
Shares held
97.9M
+15.8M (+19.3%) vs. Q2 2024
Total value
$1.90B
−$233.4M (−11.0%) vs. Q2 2024
New holders
34
92 more added
Sold out
32
90 more reduced

2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ARWR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2024: 272 institutions
Q1 2021: 289 institutionsQ2 2021: 314 institutionsQ3 2021: 297 institutionsQ4 2021: 311 institutionsQ1 2022: 307 institutionsQ2 2022: 279 institutionsQ3 2022: 278 institutionsQ4 2022: 282 institutionsQ1 2023: 257 institutionsQ2 2023: 274 institutionsQ3 2023: 257 institutionsQ4 2023: 266 institutionsQ1 2024: 273 institutionsQ2 2024: 272 institutionsQ3 2024: 272 institutionsQ4 2024: 269 institutionsQ1 2025: 264 institutionsQ2 2025: 281 institutionsQ3 2025: 303 institutionsQ4 2025: 401 institutionsQ1 2026: 437 institutionsQ2 2026: 501 institutions
Value heldQ3 2024: $1.90B
Q1 2021: $4.55BQ2 2021: $5.54BQ3 2021: $4.16BQ4 2021: $4.51BQ1 2022: $3.19BQ2 2022: $2.54BQ3 2022: $2.35BQ4 2022: $2.97BQ1 2023: $1.85BQ2 2023: $2.57BQ3 2023: $2.01BQ4 2023: $2.37BQ1 2024: $2.76BQ2 2024: $2.54BQ3 2024: $1.90BQ4 2024: $1.88BQ1 2025: $1.34BQ2 2025: $1.67BQ3 2025: $3.83BQ4 2025: $7.70BQ1 2026: $7.58BQ2 2026: $9.73B
Institutions holding ARWR and their total value by quarter
QuarterHoldersValue
Q2 2026501$9.73B
Q1 2026437$7.58B
Q4 2025401$7.70B
Q3 2025303$3.83B
Q2 2025281$1.67B
Q1 2025264$1.34B
Q4 2024269$1.88B
Q3 2024272$1.90B
Q2 2024272$2.54B
Q1 2024273$2.76B
Q4 2023266$2.37B
Q3 2023257$2.01B
Q2 2023274$2.57B
Q1 2023257$1.85B
Q4 2022282$2.97B
Q3 2022278$2.35B
Q2 2022279$2.54B
Q1 2022307$3.19B
Q4 2021311$4.51B
Q3 2021297$4.16B
Q2 2021314$5.54B
Q1 2021289$4.55B

Institutions, Q3 2024

Shares, value and share of portfolio for each institution holding Arrowhead Pharmaceuticals, Inc.; share changes are against Q2 2024.

Institutions holding ARWR in Q3 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Annis Gardner Whiting Capital Advisors, LLC0$00.00%−29−100.0%Sold out
Innealta Capital, LLC0$00.00%−11−100.0%Sold out
Toronto Dominion Bank0$00.00%−3−100.0%Sold out
Highline Wealth Partners LLC0$00.00%−1−100.0%Sold out
BlackRock Inc.––––Not filed
Hoylecohen, LLC––––Not filed